Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Thoracic 2Dermatologic 2Breast 2Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 47Triple Negative Breast Neoplasms 25Ovarian Neoplasms 8Neoplasm Metastasis 8Melanoma 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Merkel Cell 3Lung Neoplasms 2Kidney Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Thyroid Neoplasms 1

Interventions

pembrolizumab 9Cyclophosphamide 6fludarabine phosphate 4aldesleukin 3Radiotherapy 3Gemcitabine 3Drug Therapy 3Docetaxel 3Cetuximab 3temsirolimus 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2fludarabine 2entinostat 2durvalumab 2belinostat 2atezolizumab 2Sirolimus 2Paclitaxel 2Methods 2Metformin 2Irinotecan 2Interferon-alpha 2Bortezomib 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2valspodar 1tremelimumab 1tocilizumab 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × durvalumab × Breast × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Washington University School of Medicine

Phase 2 Terminated
4 enrolled 12 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡